Listened to David Epstein presentation at Morgan Stanley Healthcare Conference two days ago. He said that measurement of clinical activity in GBM is more complicated than in NSCLC. It has to be done by RANO criteria, not by measuring ORR by Recist 1.1 criteria. They need to demonstrate increase in PFS and ultimately, in OS. Their goal is to achieve six months PFS in 25% patients. Possibly, it is a reason why they already reported NSCLC data but still waiting to release GBM data in 4thQ. Measuring PFS at 6 months takes longer then ORR.
Market Data 
Markets 
AI
